Company intelligence / Profile preview

CEFO

Gwangmyeong, Gyeonggi-do, South Koreacefoadvisors.com ↗

Ownership: Private
Development stage: Other

Overview

CT01, a cell-based therapeutic agent targeting osteonecrosis of the femoral head, received phase 1 clinical approval in South Korea. The company has also developed advanced manufacturing capabilities for natural killer cell therapies and maintains GMP-certified facilities. Non-clinical efficacy tests have been completed for other pipeline candidates such as CF-M801.

Therapeutic areas: Rheumatology
Modalities: Cell therapyNatural killer cell therapy (including CAR-NK, NKT)Stem cell-based therapies
Industry: Biotech

Drug pipeline

1 asset

CF-M801

Unknown

Partnerships

Kyungpook National University HospitalKorea Research Institute of Bioscience and BiotechnologyMcGill University CanadaAnimal and Plant Quarantine Agency/Korea Racing Authority

Beyond the preview

Go deeper on CEFO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CEFO.

Explore the full profile